GlassScriptPhysician profile
Matthew Michael Sochat
NPI 1518304849
$5,548.81
in general payments reported to CMS, 2019-2025
61 companies · $2,078 in 2025
The $2,078 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $123 · 2021: $105 · 2022: $635 · 2023: $1,130 · 2024: $1,288 · 2025: $2,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,510 · Long Term Medical Supply Or Device Loan: $1,530 · Education: $256 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,509.81 |
| Long Term Medical Supply Or Device Loan | $1,529.72 |
| Education | $255.73 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,577.55 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $362.56 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $326.89 | 2021-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $282.29 | 2022-2025 | Rybrevant, Tecvayli, Darzalex |
| Celgene Corporation | $240.57 | 2022-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $224.50 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $211.73 | 2022-2025 | Lynparza, Calquence, Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $167.70 | 2022-2025 | Ninlaro |
| Ipsen Biopharmaceuticals, INC | $143.01 | 2020-2023 | Somatuline Depot, Onivyde |
| Genentech USA, INC. | $127.46 | 2022-2025 | Itovebi, Phesgo, Perjeta |
| Asd Specialty Healthcare, LLC | $126.90 | 2023 | |
| Abbvie INC. | $109.03 | 2019-2025 | Venclexta |
| Incyte Corporation | $104.35 | 2022-2023 | Jakafi |
| Genzyme Corporation | $102.58 | 2021-2024 | |
| Glaxosmithkline, LLC. | $95.49 | 2022-2025 | Ojjaara, Zejula, Jemperli |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sochat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.